ANRS 12406 EvvA Study
EvvA
Virological Failure and HIV Drug Resistance Among Adolescents Receiving Antiretroviral Treatment in Cameroon
1 other identifier
observational
289
1 country
1
Brief Summary
ANRS 12406 EvvA is an observational, longitudinal and monocentric study evaluating the virological success rate in HIV-infected adolescents on antiretroviral therapy in Cameroon. The main objective of the study is to estimate the rate of virological suppression among adolescents on antiretroviral therapy for more than 6 months in Cameroon
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 5, 2020
CompletedFirst Posted
Study publicly available on registry
October 20, 2020
CompletedStudy Start
First participant enrolled
April 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 14, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 14, 2022
CompletedApril 30, 2021
April 1, 2021
9 months
October 5, 2020
April 29, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Viral load suppression after ≥ 6 months of antiretroviral therapy
Proportion of participants with HIV-1 RNA \<1000 copies / ml after ≥ 6 months of antiretroviral therapy
Day 0
Secondary Outcomes (1)
Drug resistance after ≥ 6 months of antiretroviral therapy
3 months
Eligibility Criteria
The study will include adolescents living with HIV infection, aged 10 to 19 years and follow-up in a treatment unit in Douala, Cameroon.
You may qualify if:
- Being adolescent (aged 10 to 19) on antiretroviral therapy and followed at the Laquintinie Hospital (Douala Cameroon)
- HIV-1 infection
- Duration of antiretroviral therapy ≥ 6 months regardless of antiretroviral regimen
- For emancipated adolescents: obtaining informed consent signed by the adolescent
- For unemancipated adolescents:
- Obtaining informed consent signed by the legal representative (parent(s) or guardian(s))
- Obtaining the assent of adolescents able to understand the study (maturity and knowledge of HIV status)
You may not qualify if:
- Infection with HIV-1 or HIV-1/HIV2 co-infection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- ANRS, Emerging Infectious Diseaseslead
- Hospital Laquinitinie de Doualacollaborator
- Franceville International Center for Medical Research, Gaboncollaborator
- Institut Pasteurcollaborator
Study Sites (1)
Hôpital Laquinitie de Douala
Douala, Cameroon
Related Publications (1)
Djiyou ABD, Penda CI, Madec Y, Ngondi GD, Moukoko A, Varloteaux M, de Monteynard LA, Moins C, Moukoko CEE, Aghokeng AF. Viral load suppression in HIV-infected adolescents in cameroon: towards achieving the UNAIDS 95% viral suppression target. BMC Pediatr. 2023 Mar 15;23(1):119. doi: 10.1186/s12887-023-03943-0.
PMID: 36922769DERIVED
Biospecimen
Whole blood samples
Study Officials
- STUDY DIRECTOR
Avelin F AGHOKENG, PhD
Institut de Recherche pour le Developpement
- PRINCIPAL INVESTIGATOR
Ida C PENDA
Hôpital Laquinitie de Douala
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 5, 2020
First Posted
October 20, 2020
Study Start
April 15, 2021
Primary Completion
January 14, 2022
Study Completion
January 14, 2022
Last Updated
April 30, 2021
Record last verified: 2021-04